Skip to main content

Table 2 Laboratory results in normal control (NC), beta-thalassemic patients receiving regular blood transfusion (Thal-RT) and post-hematopoietic stem cell transplantation beta-thalassemic patients (Thal-HSCT)

From: No differences in hemostatic and endothelial activations between haploidentical and matched-donor hematopoietic stem cell transplantation in thalassemia disease

Parameter

NC

n = 20

Thal-RT

n = 28

Thal-HSCT

Classified by type of donor

Haploidentical

n = 14

Matched-donor

n = 9

VWF:Ag (%)

80.8 (67.5–108.1)

131.3* (100.3–151.5)

149.7* (127.9–162.1)

139.4* (113.2–169.9)

TNF-α (pg/ml)

0.1 (0.0–2.2)

4.4* (3.1–5.3)

3.2 (2.8–4.4)

4.7* (3.8–5.2)

TM (ng/ml)

2.7 (2.3–3.4)

ND

3.8 (2.5–4.2)

4.0 (3.5–5.5)

F1.2 (pmol/l)

125.5 (109.8–150.9)

404.1 (195.7–1048.0)

227.6# (173.2–281.2)

213.8 (190.1–271.5)

TAT (μg/l)

2.6 (2.4–3.0)

4.7 (2.0–7.0)

3.0 (2.6–4.0)

4.7 (3.7–6.3)

D-dimer (ng/ml)

224.0 (118.0–346.5)

287.2 (181.6–453.2)

254.0 (207.0–429.0)

410.0 (335.0–555.0)

  1. Abbreviations: vWF:Ag von Willebrand factor antigen; TNF-α tumor necrosis factor alpha; TM thrombomodulin; F1.2 prothrombin fragment 1 + 2; TAT thrombin-antithrombin complex; ND no data
  2. Data expressed as median (interquartile range)
  3. *, significant compared with NC, p-value < 0.05
  4. #, significant compared with Thal-RT, p-value < 0.05
  5. tested by Bonferroni